BediALynchEBSibilsky EnselmanER. Elevation in circulating biomarkers of cartilage damage and inflammation in athletes with femoroacetabular impingement. Am J Sports Med. 2013;41(11):2585-2590.
2.
BrazierJRobertsJDeverillM. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21(2):271-292.
3.
ByrdJW. Femoroacetabular impingement in athletes: current concepts. Am J Sports Med. 2014;42(3):737-751.
4.
ChangRWPellisierJMHazenGB. A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA. 1996;275(11):858-865.
5.
ClohisyJCBacaGBeaulePE. Descriptive epidemiology of femoroacetabular impingement: a North American cohort of patients undergoing surgery. Am J Sports Med. 2013;41(6):1348-1356.
6.
ColvinACHarrastJHarnerC. Trends in hip arthroscopy. J Bone Joint Surg Am. 2012;94(4):e23.
7.
CvetanovichGLChalmersPNLevyDM. Hip arthroscopy surgical volume trends and 30-day postoperative complications. Arthroscopy. 2016;32(7):1286-1292.
8.
GanzRParviziJBeckMLeunigMNotzliHSiebenrockKA. Femoroacetabular impingement: a cause for osteoarthritis of the hip. Clin Orthop Relat Res. 2003;417:112-120.
9.
KhanMOduwoleKORazdanP. Sources and quality of literature addressing femoroacetabular impingement: a scoping review 2011-2015. Curr Rev Musculoskelet Med. 2016;9(4):396-401.
10.
LodhiaPGuiCChandrasekaranSSuarez-AhedoCDirschlDRDombBG. The economic impact of acetabular labral tears: a cost-effectiveness analysis comparing hip arthroscopic surgery and structured rehabilitation alone in patients without osteoarthritis. Am J Sports Med. 2016;44(7):1771-1780.
11.
LodhiaPSlobogeanGPNoonanVKGilbartMK. Patient-reported outcome instruments for femoroacetabular impingement and hip labral pathology: a systematic review of the clinimetric evidence. Arthroscopy. 2011;27(2):279-286.
12.
RussellLBGoldMRSiegelJEDanielsNWeinsteinMC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(14):1172-1177.
13.
SiegelJEWeinsteinMCRussellLBGoldMR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996;276(16):1339-1341.
14.
WaltersSJBrazierJE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. Health Qual Life Outcomes. 2003;1:4.
15.
WeinsteinMCSiegelJEGoldMRKamletMSRussellLB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
